These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18471791)

  • 1. Mechanisms of bone metastasis in prostate cancer: clinical implications.
    Msaouel P; Pissimissis N; Halapas A; Koutsilieris M
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):341-55. PubMed ID: 18471791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bone metastasis of prostate cancer: an update].
    Tang H; Zhang ZY
    Zhonghua Nan Ke Xue; 2010 Apr; 16(4):364-7. PubMed ID: 20626169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone metastases in prostate cancer: a targeted approach.
    Storey JA; Torti FM
    Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
    Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ
    Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).
    Ye L; Kynaston HG; Jiang WG
    Int J Mol Med; 2007 Jul; 20(1):103-11. PubMed ID: 17549396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin K in the bone microenvironment: link between obesity and prostate cancer?
    Podgorski I; Linebaugh BE; Sloane BF
    Biochem Soc Trans; 2007 Aug; 35(Pt 4):701-3. PubMed ID: 17635127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic process of prostate cancer metastasis to bone.
    Tantivejkul K; Kalikin LM; Pienta KJ
    J Cell Biochem; 2004 Mar; 91(4):706-17. PubMed ID: 14991762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone and prostate cancer cell interactions in metastatic prostate cancer.
    Vela I; Gregory L; Gardiner EM; Clements JA; Nicol DL
    BJU Int; 2007 Apr; 99(4):735-42. PubMed ID: 17166237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
    Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
    J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
    Russell MR; Jamieson WL; Dolloff NG; Fatatis A
    Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A
    BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract]   [Full Text] [Related]  

  • 16. Osteoblastic metastasis in advanced prostate cancer.
    Koutsilieris M
    Anticancer Res; 1993; 13(2):443-9. PubMed ID: 8517661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ; Febbo PG
    Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
    Logothetis CJ; Navone NM; Lin SH
    Clin Cancer Res; 2008 Mar; 14(6):1599-602. PubMed ID: 18347159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.